ReviewLe infezioni in medicina2023
Antivirals for the treatment of Monkeypox: utilization in the general and HIV-positive population and gaps for research. A short narrative review.
Review in Le infezioni in medicina, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 4 citations in OpenAlex.
- A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026Review
- Drivers of Viral Spillover: An Examination of How Pathogens Spread.Pathogens (Basel, Switzerland) · 2026Review
- A Global Health Alert on the Re-Emergence of Mpox a Viral Zoonotic Illness Its Prevention and Management: A Narrative Review.Health science reports · 2026Article
- The evolving mpox threat (2022-2024): clade dynamics, immune evasion, and escalating global health challenges.Frontiers in cellular and infection microbiology · 2025Review
- Evaluating the advancements and efficacies in pharmacological Mpox treatments: a comprehensive review.Frontiers in pharmacology · 2025Review
- [Mpox in humans: an overview of the 2022-2023 epidemic].Revista medica del Instituto Mexicano del Seguro Social · 2024Review
- The Resurgence of Mpox: A New Global Health Crisis.Le infezioni in medicina · 2024Article
- Update on Mpox: a brief narrative review.Le infezioni in medicina · 2023Review
- Immunoinformatics and reverse vaccinology approach in designing a novel highly immunogenic multivalent peptide-based vaccine against the human monkeypox virus.Frontiers in molecular biosciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monkeypox (Mpox) is an emerging viral disease caused by the monkeypox virus (MPXV), a double-stranded DNA virus member of the genus Orthopoxvirus, first reported in humans in 1970. Since May 2022, a global spread of the infection has occurred that the World Health Organization (WHO) declared a public health emergency. In view of the global threat, efforts have been devoted to bolstering the disease spread as well as identifying viable therapeutic modalities. People living with HIV may be at an increased risk of adverse outcomes and may require antiviral treatment. With regard to antiretroviral drugs agents, the anticipated adverse drug reactions do not preclude the co-administration of combined antiretroviral therapy and antivirals for mpox. More data on treatment recommendations and efficacy in patients with immunodeficiency due to HIV is needed. In this review, tecovirimat, cidofovir and brincidofovir - antiviral agents with activity against MPXV and other Orthopoxviruses are reviewed, their utilization in vulnerable patient groups affected by mpox such as people living with HIV and possible gaps for future research. Tecovirimat is an inhibitor of the Orthopoxvirus VP37 envelope wrapping protein thus rendering enveloped virus formation impossible. Cidofovir and its prodrug brincidofovir interfere with DNA synthesis through DNA polymerase inhibition. Ongoing research is intensified to verify efficacy and applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.